
The Material Advantage Podcast with Dan Noakes & Rachel Myall
Episode 2
<p>Over the past five years, there has been a rush of investment into alternative materials and chemicals. Biomaterials funding for example peaked at $1.7 billion in 2022, cooled to $583 million in 2024 and was recovering towards roughly $1.5 billion for 2025 according to Net Zero Insights and World Bio Markets Insights. So why haven't there been more success stories? We discuss what has gone right, what has gone wrong, the role of buyers and supply chains as well as investors, and how innovators are rethinking how to fundraise and scale.</p>

